Previous 10 | Next 10 |
BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OTL-203, a hematopoietic stem cell (HSC) gene therapy ...
Summary Orchard Therapeutics is one of these tickers that, after losing approximately 65% of its value over the past twelve months, has a market cap of around $55M. ORTX has a price-to-book of 0.45 and an enterprise value of about -$32M. What is more, ORTX has a price-to-sales of 2.72x....
Orchard Therapeutics PLC (ORTX) Q1 2022 Earnings Conference Call May 12, 2022, 08:00 ET Company Participants Bobby Gaspar - CEO Braden Parker - Chief Commercial Officer Frank Thomas - President & COO Leslie Meltzer - Chief Medical Officer Conference Call Participants Brendan Smith - Cowen...
Orchard Therapeutics press release (NASDAQ:ORTX): Q1 GAAP EPS of -$0.35 misses by $0.10. Revenue of $5.52M beats by $1.48M. The company expects that its existing cash, cash equivalents and investments of $199M will fund its anticipated operating, debt service and capital expenditure requireme...
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy ® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA fil...
Orchard Therapeutics (NASDAQ:ORTX) is scheduled to announce Q1 earnings results on Thursday, May 12th, before market open. The consensus EPS Estimate is -$0.24 (+22.6% Y/Y) and the consensus Revenue Estimate is $4.04M (+304.0% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward rev...
AADI,ACHR,ACTG,ADN,AEG,OTCPK:ALIZF,ALT,AMTX,OTCPK:ARNGF,ARQQ,ATY,BAM,BGRY,BKKT,BT,CAMT,CASI,CORR,CPG,CYBR,CYXT,DAVA,DCBO,DRIO,EMAN,EURN,GENI,HIMX,OTCPK:HNHAF,HUT,IS,KNOP,KT,LQDA,MGIC,OTCPK:MKGAF,ML,MOGO,MTNB,NETI,NICE,OTCPK:NSANY,NVMI,ORTX,PCT,OTCPK:PEYUF,OTCQX:QTRHF,RDCM,OTCPK:RWEOY,SCYX,SFL...
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 1...
BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 20...
BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche Krankenversicherung Spitzenverband (GKV-SV) which will result in reimbursed access to Libmeldy ® (atid...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....